| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/13/2002 | US20020072539 For therapy of tumor necrosis factor(TNF), edema, neurological deficits, stroke and for therapy of pathological conditions caused by TNF-alpha |
| 06/13/2002 | US20020072538 NMDA NR2B antagonists for treatment |
| 06/13/2002 | US20020072531 Useful as anticoagulants in mammals; inhibitors of factor Xa |
| 06/13/2002 | US20020072526 Orally active salts with tyrosine kinase activity |
| 06/13/2002 | US20020072525 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072524 Aryl fused azapolycyclic compounds |
| 06/13/2002 | US20020072519 Useful as psychotherapeutic agents |
| 06/13/2002 | US20020072518 Bicyclic alphavbeta3 antagonists |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 06/13/2002 | US20020072488 Amino acid sequences of human transporter peptides and proteins that are related to the sugar transporter subfamily; identifying modulators of the transporter peptides |
| 06/13/2002 | US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia) |
| 06/13/2002 | US20020072107 Human osteoclast derived cathepsin |
| 06/13/2002 | US20020072101 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 06/13/2002 | US20020072090 Hr-1 receptor |
| 06/13/2002 | US20020072066 Human osteoporosis gene |
| 06/13/2002 | US20020071878 Anti proliferative preparations |
| 06/13/2002 | US20020071874 Compositions containing therapeutically active components having enhanced solubility |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071840 Method of therapeutic administration of anti-CD40L compounds |
| 06/13/2002 | US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 06/13/2002 | US20020071816 Contain alph-hydroxytetronic acid or a derivative, and, in some cases, hydroquinone, an alpha -hydroxy acid such as glycolic acid, and a fatty acid ester of ascorbic acid such as ascorbyl palmitate. |
| 06/13/2002 | DE10061334A1 Verwendung von aus embryonalen Stammzellen hergeleiteten Zellen zur Erhöhung der Transplantationstoleranz und zur Wiederherstellung zerstörten Gewebes Using derived from embryonic stem cells to increase transplant tolerance and restore damaged tissue |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2437048A1 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | CA2436984A1 Urea substituted imidazoquinoline ethers |
| 06/13/2002 | CA2436983A1 Sulfonamido ether substituted imidazoquinolines |
| 06/13/2002 | CA2436916A1 Use of pyrazolo[4,3-d]pyrimidines |
| 06/13/2002 | CA2436870A1 Substituted anthranilic acids |
| 06/13/2002 | CA2436662A1 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2436311A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2431203A1 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | CA2431202A1 Human sprouty-4 polypeptide |
| 06/13/2002 | CA2431187A1 Macroheterocylic compounds useful as kinase inhibitors |
| 06/13/2002 | CA2431181A1 Nootropic effect enhancer |
| 06/13/2002 | CA2431171A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| 06/13/2002 | CA2431166A1 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 06/13/2002 | CA2431151A1 Heterocyclic ether substituted imidazoquinolines |
| 06/13/2002 | CA2431040A1 Substituted imidazopyridines |
| 06/13/2002 | CA2431005A1 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2430993A1 G-protein coupled receptors |
| 06/13/2002 | CA2430989A1 Method of collecting placental stem cells |
| 06/13/2002 | CA2430951A1 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 06/13/2002 | CA2430844A1 Aryl ether substituted imidazoquinolines |
| 06/13/2002 | CA2430769A1 Novel estrogen receptor ligands and methods iii |
| 06/13/2002 | CA2430716A1 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof |
| 06/13/2002 | CA2430624A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430536A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/13/2002 | CA2430466A1 Klainetin and derivatives thereof, method for their production and the use of the same |
| 06/13/2002 | CA2430412A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/13/2002 | CA2430376A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| 06/13/2002 | CA2430355A1 Tetralone derivatives as antitumor agents |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2430191A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/13/2002 | CA2429769A1 Methods of treatment involving human mda-7 |
| 06/13/2002 | CA2429728A1 Tyrosine kinase inhibitors |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428208A1 Lipid-associated molecules |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | CA2427430A1 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | CA2425396A1 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 06/13/2002 | CA2363575A1 Crystal structure |
| 06/12/2002 | EP1213353A1 Peptide leukotriene receptor |
| 06/12/2002 | EP1213291A1 Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders |
| 06/12/2002 | EP1213289A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists |
| 06/12/2002 | EP1213287A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 06/12/2002 | EP1213285A2 4,5-dipheny-oxazole derivatives and their use as platelet aggregation inhibitors |
| 06/12/2002 | EP1213281A1 Novel amide derivatives |
| 06/12/2002 | EP1213031A2 Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist |
| 06/12/2002 | EP1213026A1 Brain cell or nerve cell protecting agents comprising ginseng |
| 06/12/2002 | EP1213025A1 Cosmetic and/or dermopharmaceutical composition containing extracts obtained from the leaves of Argania spinosa |
| 06/12/2002 | EP1213019A2 Method for treating chronic obstructive pulmonary disease |
| 06/12/2002 | EP1212941A2 Modulating ramp activity |
| 06/12/2002 | EP1212621A1 Screening for agents modulating tgf-beta cell signalling |
| 06/12/2002 | EP1212616A2 Inhibitors of binding between proteins and macromolecular ligands |
| 06/12/2002 | EP1212455A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 06/12/2002 | EP1212453A1 Method to identify gene function using small molecule probes |
| 06/12/2002 | EP1212436A2 Protein phosphatase and kinase proteins |
| 06/12/2002 | EP1212428A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 06/12/2002 | EP1212418A2 p193 PROTEINS AND NUCLEIC ACIDS, AND USES THEREOF |
| 06/12/2002 | EP1212416A2 Nucleic acid based modulators of gene expression |
| 06/12/2002 | EP1212413A1 A transmembrane trap for isolating membrane bound proteins |
| 06/12/2002 | EP1212410A2 Dna encoding the human serine protease eos |
| 06/12/2002 | EP1212408A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 06/12/2002 | EP1212405A2 Use of cytokines, cells, and mitogens to inhibit graft versus host disease |
| 06/12/2002 | EP1212362A2 Card proteins involved in cell death regulation |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212353A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf) |
| 06/12/2002 | EP1212350A1 A process for the preparation of h-tyr-d-ala-phe(f)-phe-nh 2? |
| 06/12/2002 | EP1212346A1 Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212343A1 52 human secreted proteins |
| 06/12/2002 | EP1212339A1 2'-o-acetamido modified monomers and oligomers |
| 06/12/2002 | EP1212329A2 Amine derivatives of benzo[4,5]thieno[2,3-d]pyrimidine |
| 06/12/2002 | EP1212327A2 Pyrazolopyrimidines as therapeutic agents |
| 06/12/2002 | EP1212326A1 PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS |
| 06/12/2002 | EP1212322A2 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/12/2002 | EP1212318A1 Substituted indolinones as tyrosine kinase inhibitors |